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Abstract 
Background: Diabetic nephropathy (DN) is a late complication in both type 1 diabetes mellitus (T1DM) and T2DM. 
Already at an early stage of DN morphological changes occur at the cell surface and in the extracellular matrix where 
the majority of the proteins carry N-linked glycosylations. These glycosylated proteins are highly important in cell 
adhesion and cell–matrix processes but not much is known about how they change in DN or whether the distinct 
etiology of T1DM and T2DM could have an effect on their abundances.
Method: We enriched for the N-glycosylated kidney proteome in db/db mice dosed with insulin or vehicle, in strep-
tozotocin-induced (STZ) diabetic mice and healthy control mice dosed with vehicle. Glycopeptides were analyzed 
with label-free shotgun mass spectrometry and differential protein abundances identified in both mouse models 
were compared using multivariate analyses.
Results: The majority of the N-glycosylated proteins were similarly regulated in both mouse models. However, dis-
tinct differences between the two mouse models were for example seen for integrin-β1, a protein expressed mainly 
in the glomeruli which abundance was increased in the STZ diabetic mice while decreased in the db/db mice and 
for the sodium/glucose cotransporter-1, mainly expressed in the proximal tubules which abundance was increased 
in the db/db mice but decreased in the STZ diabetic mice. Insulin had an effect on the level of both glomerular and 
tubular proteins in the db/db mice. It decreased the abundance of G-protein coupled receptor-116 and of tyrosine-
protein phosphatase non-receptor type substrate-1 away from the level in the healthy control mice.
Conclusions: Our finding of differences in the N-glycosylation protein profiles in the db/db and STZ mouse models 
suggest that the etiology of DN could give rise to variations in the cell adhesion and cell–matrix composition in T1DM 
and T2DM. Thus, N-glycosylated protein differences could be a clue to dissimilarities in T1DM and T2DM at later stages 
of DN. Furthermore, we observed insulin specific regulation of N-glycosylated proteins both in the direction of and 
away from the abundances in healthy control mice.
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Background
The prevalence of both T1DM and T2DM is increasing 
and together they affect over 340 million people world-
wide. The insulin-dependent T1DM covers 5–10  % of 
the cases where as T2DM comprise 90 % of the disease 
and the prevalence increases more rapidly [1–3]. Despite 
different etiology, both T1DM and T2DM result in a 
20–30  % occurrence of DN. Type 2 DM patients often 
go undiagnosed for several years, which means that DN 
often is diagnosed at a later stage in development. The 
larger heterogeneity of T2DM patients is reflected in 
larger structural differences in the kidneys of patients 
with DN compared to T1DM patients with DN [4, 5]. 
The structural changes of T1DM and T2DM during 
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progression of DN are however roughly similar [5, 6] 
with tubular and glomerular basement membrane (BM) 
thickening, extracellular matrix (ECM) and mesangial 
expansion and changes in the proteoglycan structure 
both at the cell surface and in the extracellular space [7].
In the kidney-specific processes of blood filtering, 
protein retention and reabsorption of fluid and small 
molecules, the extracellular matrix and its connection 
to cellular surfaces are regions of high functional impor-
tance. In the glomeruli the podocytes guard the slit dia-
phragm and prevent the loss of larger molecules from 
the blood to the primary urine and in the tubules solute 
and water reabsorption is managed [8]. A large propor-
tion of the extracellular and cell surface proteins involved 
in those processes, including proteoglycans, carry glyco-
sylation on asparagine (N) residues [9]. The N-linked gly-
cosylation pattern is controlled by enzymatic processes 
as compared to the non-enzymatic, unspecific glucose 
dependent glycation of proteins, measured by the level of 
glycated hemoglobin-A1c (HbA1c%) [10, 11].
Addressing changes in the extracellular space and the 
cell surface can be a challenge since this sub-proteome 
may be difficult to map due to technical aspects in a regu-
lar proteome analysis or in a non-biased way in antibody 
based analysis [12]. Changes in the N-glycosylated pro-
teome have repeatedly been shown in various diseases 
and cell-types [12–15]. Since N-linked glycosylation is 
a hallmark of cell membrane and extracellular proteins 
[16, 17] and early kidney changes in DN are observed at 
those locations [8] we enriched for glycosylated peptides 
with hydrazide capture [18] to target this sub proteome. 
By using label free shotgun mass spectrometry, we com-
pared the N-glycosylated fraction of the kidney pro-
teomes from two regularly used diabetic mouse models; 
the STZ-induced diabetic mice with reduced pancreatic 
beta cell mass and the obese db/db mice with deficient 
leptin receptor signaling leading to obesity, insulin resist-
ance and finally overt diabetes. Both mouse models are 
characterized by having early signs of DN in the form of 
increased albumin excretion rates (AER) [19] driven by 
hyperglycemia.
Hyperglycemia has been shown to promote DN by 
increasing oxidative stress [20, 21] and maintaining stable 
normal blood glucose (BG) levels has a paramount posi-
tion in diabetes care [22, 23]. In T1DM, insulin is the only 
treatment option adequately lowering BG levels. Type 2 
DM can be managed with several different compounds 
in the initial phases in order to rescue the reduced insu-
lin sensitivity. At later stages in T2DM insulin adminis-
tration can be required due to decreased beta-cell mass 
and impaired insulin secretion [24]. The effects of insulin 
on the N-glycosylation pattern in DN are not known but 
changes in proteoglycans are reported in DN and altered 
glycosylation levels are well known features from diseases 
like cancer [13]. In the kidneys of STZ diabetic rats, the 
glycosylation pattern was recently shown to be altered 
over time [25], however, it is not known if the different 
etiologies of diabetes give rise to variations in the glyco-
sylation pattern in DN.
We sought to compare the N-glycosylated protein 
profiles in the kidneys of the db/db and STZ induced 
diabetic mouse models since the two models represent 
separate etiologies of diabetes and both exhibit traits of 
early stage DN [19]. In addition, the effects of insulin 
on N-glycosylation was investigated in the db/db mouse 
model kidney to elucidate its influence on the extracellu-
lar and cell surface proteome as previously described by 
Bausch-Fluck et al. [15]. Insulin has earlier been reported 
to contribute to podocyte survival which is important for 
maintaining proper glomerular function [26, 27].
Results
Experimental design and mouse parameters
This work uses N-glycosylation capture to compare the 
N-glycosylated kidney proteomes of the STZ induced 
diabetic and db/db mouse models, two mouse models 
frequently used in diabetes research. Both mouse mod-
els reflect the early stage of DN and do not progress to 
develop the severe types of DN and end stage renal dis-
ease (ESRD) seen in human diabetic subjects due to their 
shorter life span. A schematic timeline for the two mouse 
models is illustrated in Fig. 1a and the proteomics work-
flow is shown in Fig. 1b.
The STZ diabetic mice reached 33.4  ±  1.45  mM in 
BG 10 weeks after diabetes induction relative to a fairly 
stable level of 6.06 ±  1.28  mM throughout the study in 
the healthy NoSTZ control group. Body weight in the 
STZ mice did not change much from baseline and was 
~5  g lower than controls at termination (25.3 ±  1.2 vs. 
30 ± 0.5 g).
The AER was ~tenfold higher in the STZ mice at 
578 ± 117 µg/24 h compared with 55.7 ± 12.0 µg/24 h in 
the NoSTZ controls at the final sampling time point.
The db/db mice did not reach the same level of 
hyperglycemia, but peaked at 23.12 ± 2.54 mM relative 
to 8.91 ±  0.28  mM in the db/+ controls at 22  weeks 
of age. In spite of the lower levels of glycaemia in the 
db/db mice, HbA1c% was similar or slightly higher at 
termination compared to the STZ mice (8.52 ±  0.7 % 
for the db/db and 7.60  ±  0.13  % for the STZ mice), 
indicating that the accumulated diabetic burden was 
comparable in the two mouse models. Diabetes in 
the db/db model comes secondary to overeating and 
body weight in this model peaked at 54  ±  3.2 ver-
sus 31  ±  0.8  g at 16  weeks of age (db/db vs. db/+). 
After this the body weight stabilized indicating that 
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insulin production in the mice failed to keep up 
with the increasing insulin resistance the animals 
develop [19]. The AER was increased about eightfold 
in the db/db model (930.2  ±  184.8  µg/24  h in db/db 
vs. 112.2 ±  54.5  µg/24  h in db/+), however, both the 
healthy db/+ controls and diabetic db/db mice had 
about twice the AER as the SV129 mice indicating an 
effect of the background. In the db/db insulin mice 
Fig. 1 Timeline, workflow and result overview for the db/db and STZ mouse models. a The timeline for the db/db and STZ mouse models with 
indications for time of arrival, STZ intervention, dosing start of insulin or vehicle, analyses, measurements and termination. Blood glucose and body 
weight were monitored weekly in both mouse models, HbA1c% was analyzed weekly in the db/db model and 6 and 10 weeks after STZ interven-
tion in the STZ mouse model. The albumin excretion rate, AER, was analyzed at three time points in both mouse models; in the db/db model at 
baseline, 6 and 12 weeks after insulin dosing start and in the STZ model at baseline, 6 and 10 weeks. The STZ study was terminated 10 weeks after 
the STZ intervention (animals 18 weeks old) and the db/db study was terminated 12.5 weeks after baseline (dosing start of insulin or vehicle) 
when the animals were 22 weeks old. In both mouse models the included diabetic animals had elevated AER and BG over 16 mM. b The workflow 
for protein purification, data and statistical analyses for the db/db and STZ mouse models. In c a Venn diagram of the N-glycosylated proteins in 
the db/db and STZ mouse models is shown. The protein quantification is based on N-glycosylated unique peptides. In total, 395 N-glycosylated 
proteins were identified in the db/db mouse model and 505 were identified in the STZ mouse model with P < 0.05. All 395 and 505 proteins were 
respectively used in the IPA as the final step shown in panel B. 153 proteins were identified in both mouse models and those proteins were used in 
the multivariate analyses
Page 4 of 17Liljedahl et al. Clin Proteom  (2016) 13:22 
HbA1c% was slightly increased at baseline compared 
to the db/db vehicle mice but after 12 weeks of insulin 
dosing, at the age of 22  weeks, HbA1c% was reduced 
in the db/db insulin mice (6.78  ±  0.23  %) compared 
to the db/db vehicle mice (8.52 ± 0.7 %). At 22 weeks 
of age there was no significant difference in AER or 
BG, but the body weight continued to increase in the 
db/db insulin mice and was after 12  weeks of dosing 
62.3  ±  0.9  g compared to 53.7  ±  3.8  g in the db/db 
vehicle mice. Mouse parameters can be seen in Table 1.
Visualizing the STZ and db/db mouse models 
with multivariate analyses and clustering
Analyses of the N-glycosylated sub-proteome does not 
yield as many identified proteins as regular proteomics 
analyses do, but provides the opportunity of examining 
otherwise undetected proteins [12]. A challenge is that the 
proteins need to include a unique peptide with the NXS/T 
N-glycosylation motif. Approximately 50  % of the identi-
fied peptides in both the STZ and db/db datasets carried 
an Asn to Asp modification. Protein assembly based on the 
formerly N-glycosylated peptides resulted in 505 identified 
proteins from 2602 formerly N-glycosylated peptides in the 
STZ mouse model (see Additional file 1a) and 395 proteins 
from 3564 highly formerly N-glycosylated peptides in the 
db/db mouse model (see Additional file 1b). Of the identi-
fied proteins in the two mouse models, 153 proteins were 
identified as shared in both as illustrated in Fig.  1c. The 
fact that several proteins only were identified in one mouse 
model does not mean that the protein not is present in 
the other mouse model. It is most likely a result of under-
sampling or low protein abundance resulting in no unique 
detected formerly N-glycosylated peptide in those proteins. 
All the proteins within each mouse model were included 
in the principal component analysis (PCA) and orthogonal 
partial least square discriminant analysis (OPLS-DA), the 
statistics are shown in an Additional file 2: Panel A. In the 
PCA of the STZ mouse model, the STZ and NoSTZ groups 
were not clearly separated (Fig. 2a). A 3D model shown in 
an Additional file 2: Panel B revealed though that there was 
a degree of separation but the first and second principal 
components were not separating the groups. The separa-
tion of the groups in the PCA of the STZ mice seemed to 
be more dependent on the degree of perfusion of the kid-
neys. The supervised OPLS-DA clearly separated the STZ 
and NoSTZ mouse groups (Fig. 2b). The healthy db/+ mice 
were clearly separated from the two db/db mouse groups 
dosed with insulin or vehicle in the PCA (Fig.  2c). Here 
there was a weak separation of the db/db insulin and db/db 
vehicle groups, a turned 3D plot is shown in an Additional 
file 2: Panel C. In the OPLS-DA the db/db vehicle and insu-
lin groups were clearly separated (Fig.  2d). Applying hier-
archical clustering on the STZ mouse model resulted in 
87 proteins with P < 0.05 and there was a clear separation 
between the expression pattern in the healthy NoSTZ and 
the diabetic STZ mice (Fig. 2e). The hierarchical clustering 
of the healthy db/+ and db/db vehicle groups resulted in 
227 proteins with P < 0.05 (Fig. 2f). The 153 proteins that 
were identified in both mouse models were selected in the 
respective OPLS analysis of the two mouse models. The 
proteins not identified in both datasets were excluded in the 
continued comparison of the N-glycosylated proteome. The 
reason for only including proteins identified in both mouse 
models, is that absent proteins in one mouse model in fact 
most likely still could be present in the mouse model with-
out being detected in the MS analysis due to low abundance 
resulting in no unique identified formerly N-glycosylated 
peptides. Examples of a few of the proteins only identified 
in the STZ mouse model can be seen in an Additional file 3: 
Panels A–B. In the OPLS analyses, proteins with a SIMCA 
variable of importance for the projection (VIP) score above 
1 in both mouse models were selected, resulting in 27 shared 
proteins of importance in the separation of the healthy and 
diabetic mice in both the STZ and the db/db mouse model. 
These proteins were examined with univariate analyses.
Quantitative comparison of the N‑glycosylated proteomes 
of the mouse models
The univariate analyses revealed that 11 of the 27 shared 
proteins of importance had significantly changed pro-
tein abundances when compared between the diabetic 
and the healthy mice in both mouse models (Table  2). 
Mean ± SD, numbers of peptides used in quantitation and 
Mascot score for the 27 proteins can be seen in an Addi-
tional file 1c. The abundances of the three proteins galec-
tin-3 binding-protein (GAL-3BP), integrin-α3 (ITGA3) 
and lysosomal membrane glycoprotein-1 (LAMP1) were 
increased in the diabetic mice in both models and the four 
proteins family with sequence similarity 151, member-A 
(F151A), cadherin-related family member 5 (CDHR5), 
meprin-α subunit-β (MEP1B) and high-affinity aspartate/
glutamate transporter-6 (SLC1A6) were decreased in the 
diabetic mice compared to the healthy mice in both mouse 
models, examples are shown in Fig.  3a, b. An inversed 
protein regulation in the STZ and db/db mice was seen for 
the four proteins ITGB1, SGLT1, prominin-1 (PROM1) 
and alkaline phosphatase (ALPL) as seen in Fig.  3c. For 
the remaining 16 of the 27 common most important pro-
teins the univariate analyses revealed significant change 
in the protein abundance in the db/db mouse model but 
not in the STZ mouse model. The 16 proteins are listed 
in an Additional file  1d. Among those 16 proteins were 
the sodium/potassium-transporting ATPase subunit-β1 
(ATP1B1) and integrin-αM (ITGAM). Although no sig-
nificant change was seen in the univariate analysis, the 
16 proteins were important in the multivariate modeling 
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of the STZ and healthy NoSTZ mouse groups. There was 
a trend towards changed protein abundances in three of 
the proteins and in two of them, the adhesion G protein-
coupled receptor E5 (CD97) and carcinoembryonic anti-
gen-related cell adhesion molecule-1a (CEACAM1), the 
trend was towards an opposite protein regulation in the 
STZ mouse model compared to the db/db mouse model 
(Fig. 3d) whereas the serine/cysteine peptidase inhibitor, 
clade A6 (SERPINA6) had a trend towards abundances 
similar to the ones in the db/db mouse model.
Ingenuity pathway analysis
Ingenuity pathway analysis (IPA) was conducted based 
on the fold changes of all identified proteins from each 
mouse model. With a small discrepancy in the precise 
protein composition, the same top network was iden-
tified in the two mouse models, although some of the 
included proteins had oppositely regulated protein 
abundances (Fig.  4a, b). The four top rated identified 
networks within each mouse model are listed in Table 3 
with the proteins included in the network and the major 
function of the involved proteins. The top rated network 
involved small molecule biochemistry and renal and 
urological system development. Included in the network 
were ATP1B1, F151A and MEP1B, all three among the 
VIP proteins in the separation of the diabetic and healthy 
mice identified in the multivariate analysis. The proteins 
in the subsequent networks 2, 3 and 4 were overlapping 
Table 2 Selected proteins identified in both mouse models with opposite or similar protein regulation
11 of the 27 VIP proteins had significantly different abundances in both the STZ and the db/db mouse models. Uniprot accession number, name of the protein and 
a short name is shown for all included proteins together with the direction of change in protein abundance level in the diabetic mice compared to the healthy mice 
within each mouse model and the P value. AIn PROM1, there was significant difference in intragroup variance. Two-tailed Student’s t test for equal variance was used 
for P value calculations except for the cases where insulin had an effect on the protein level, indicated byB. One-way ANOVA with Tukey post hoc test for correction of 
multiple comparisons was used for db/db insulin and db/db vehicle comparisons. P < 0.05 was considered significant. CKidney compartments were obtained from The 
Human Protein Atlas [28] using antibody staining where G glomerulus, T tubulus, ND no detected protein, L low, M medium, H high protein expression, RNR means 
that RNR was detected in the indicated compartment but no protein expression has been confirmed. Tr trend, with P < 0.1, > 0.05
Uniprot ID Description Short 
name











P09055 Integrin beta-1 ITGB1 Up <0.012 Down <0.002 G = H, T = L
Q8C3K6 Sodium/glucose  
cotransporter 1
SGLT1 Down <0.018 Up <0.008 T = M
O54990A Prominin-1 PROM1 Down <0.049 Up <0.001 T = H
Q3TQ02 Alkaline phosphatase,  
unreviewed
ALPL Down <0.037 Up <0.001 T = M
Q3TA96 Lysosomal membrane  
glycoprotein 1, unreviewed
LAMP1 Up <0.011 Up <0.018 G = H, T = H
Q07797 Galectin-3-binding protein GAL-3BP Up <0.001 Up <0.001 G = L, T = L
Q62470-2 Integrin alpha-3, isoform 2 ITGA3 Up <0.03 Up <0.001 G = M, T = H
Q8QZW3 Family with sequence  
similarity 151, member A





A0PJK7 Cadherin-related family  
member 5, unreviewed





Q61847-2 Meprin A subunit beta,  
isoform 2
MEP1B Down <0.008 Down <0.002 ND, RNA ND
Q6IR20 Solute carrier organic anion 
transporter family, member 
1a6, unreviewed




G = L, T = L
(See figure on previous page.) 
Fig. 2 Multivariate analyses. a A PCA and b an OPLS-DA of the STZ mouse model where all 505 identified proteins were included. The healthy 
NoSTZ and diabetic STZ mouse groups were not well separated in the unsupervised PCA, but were well separated in the supervised OPLS-DA. c A 
PCA and d an OPLS-DA of the db/db mouse model including all 395 identified proteins. The healthy db/+ group was clearly separated from the db/
db vehicle and db/db insulin groups in both multivariate models. In the PCA, the two db/db groups were not well separated, but they were clearly 
separated in the OPLS-DA. Statistics of the multivariate models are shown in an Additional file 2: Panel A. e A heat map with hierarchical clustering 
of the NoSTZ and STZ mouse groups including 87 proteins with P < 0.05 cutoff. Panel F shows a heat map with hierarchical clustering of the db/+ 
and db/db mouse groups including 227 proteins with P < 0.05 cutoff. The clustering was done using Qlucore v. 3.2





































































































































































































































































































































































































































































Fig. 3 Differences and similarities between the db/db and STZ mouse model. Panel A shows proteins with higher protein abundance in the STZ 
and db/db vehicle mouse groups compared to the healthy NoSTZ and db/+ control groups in the two mouse models. Panel B shows proteins 
with lower abundances in the STZ and db/db vehicle mouse groups compared to their healthy littermates. Panel C shows proteins with differently 
affected protein abundances in the two mouse models. Panel D shows proteins with significantly regulated protein abundance in the db/db mouse 
model and a trend to significant regulation in the STZ mouse model and thereby a trend towards differently affected protein regulation in the two 
mouse models. Two-tailed Students t test was used for calculation of significance level when 2 groups were included and one-way ANOVA with 
Tukey post hoc test was used for the calculations including the db/db insulin group in the db/db mouse model. Graphs are shown with mean and 
95 % CI and P < 0.05 is considered significant
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within the two mouse models. In those networks ITGB1 
(Fig. 3c) was included, one of the common 27 VIP pro-
teins with inversed protein expression in the two mouse 
models. Furthermore, laminin-α1 (LAMA1) appeared 
in the top 2–3 rated IPA networks and although not 
included among the VIP proteins due to different Uni-
prot accession numbers (P19137 in the STZ and F8VQ40 
in the db/db mice, 99.7 % shared sequence similarity), it 
had significantly lower protein expression in the diabetic 
compared to the healthy mice in both mouse models 
(Fig. 3b).
The effect of insulin on the db/db mice
In addition to the differences and similarities between the 
N-glycosylated proteomes of the STZ and db/db mouse 
models, we investigated the effect of insulin on the db/
db mouse model. The db/db insulin group was poorly 
separated from the db/db vehicle mice in the unsuper-
vised PCA (Fig. 2c) although a 3D projection of the PCA 
showed that the db/db insulin and db/db vehicle groups 
were separable (see Additional file 2: Panel C). The db/db 
insulin group was clearly separated from the db/db vehi-
cle in the supervised OPLS analysis (Fig. 2d). When com-
paring the db/db insulin mice to the db/db vehicle mice, 
173 of the 395 identified proteins had a VIP score above 1 
in the OPLS model and a hierarchical clustering resulted 
in 37 proteins with P < 0.05.
Insulin had a significant effect on the protein abun-
dance of F151A, SLC1A6, Hyaluronoglucosaminidase-2 
(HYAL2) and SIRPA (Figs.  3b, 5a), included in the VIP 
proteins and there was a trend towards an effect on an 
additional four of the 27 proteins, namely CDHR5, car-
bonic anhydrase-12 (CAR12), CD97 and gamma-glu-
tamyltransferase 5 (GGT5) as shown in Table  2 and 
Additional file  1d. Insulin also had an effect on 12 pro-
teins not included among the VIP proteins but within the 
153 proteins common to both the STZ and db/db mouse 
models. These 12 proteins are listed in Table 4 with the 
significance of the protein expression levels, supple-
mentary protein data can be found in Additional file 1c. 
In three of these proteins; LAMA1, GPR116 and acti-
vated leukocyte cell adhesion molecule (ALCAM) insu-
lin had an effect on the protein abundances in the db/db 
mice away from the healthy db/+ mice (Figs. 3b, 5a). In 
tripeptidyl peptidase I (TPP1), low-density lipoprotein 
receptor-related protein-2 (LRP2) and cleft lip and pal-
ate associated transmembrane protein-1 (CLPT1) insulin 
increased the abundance in the db/db mice towards the 
levels in the healthy db/+ vehicle mice and in 6 proteins 
here among hypoxia-upregulated protein-1 (HYOU1), 
alanyl (membrane) aminopeptidase (ANPEP) and sodium 
channel beta-4 subunit (SCNB4) insulin decreased the 
abundances, also in this case towards the protein levels in 
the healthy db/+ control mice (example in Fig. 5b).
Fig. 4 Shared top IPA network but with differences in protein regulation. a The IPA top-rated network for the STZ mouse model and b the db/db 
model. The fold change in the diabetic compared to the healthy control mice is illustrated with green indicating reduced levels and red indicating 
increased levels in the diabetic mice. In IPA, the total 505 and 395 proteins from the STZ and db/db mouse models respectively were included and 
several of the proteins in the top rated networks were identified in both mouse models. Of those proteins, some had opposite regulation in the two 
mouse models, although the difference in fold-change was too small to be significant in combination with low power due to low sample number; 
STZ, n = 6 in each group and db/db, n = 5 in each group
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Discussion
In this study we focused on the N-linked glycosylated pro-
teome of the kidney in two well-known mouse models for 
diabetes with early DN; the STZ model where diabetes is 
induced by repeated intermediate doses of STZ resulting 
in a reduction of the beta cell mass and the obese db/db 
model with insulin resistance and later beta cell failure [19]. 
In both the STZ and the db/db mice we saw increased lev-
els of HbA1c% indicative of diabetes and increased albumi-
nuria compared to the healthy control mice, implying early 
traits of DN. There was a comparable increase in HbA1c% 
between the healthy control and the diabetic groups in the 
two mouse models indicating similar degrees of diabetes 
despite the separate etiology in the two mouse models. 
Diabetes nephropathy is a late complication that in T1DM 
develops a decade or later after diabetes is diagnosed [29]. 
It is therefore noteworthy that no mouse has a lifespan that 
is long enough to allow them to reach the later stages of 
renal failure seen in human subjects with DN [19].
We detected a higher number of significant protein 
changes within the db/db mouse model compared to 
the STZ mouse model between the shared proteins. An 
explanation could be that some of the proteins with the 
largest differences within the STZ mouse model not 
were identified in the db/db mouse model and were not 
included in the model-to-model comparison. Five of 
these STZ mouse model specific proteins are shown in 
Additional file  2: Panels A–B. Proteins not detected in 
one mouse model could be present at lower levels in the 
mouse model or could have lower levels of N-glycosyla-
tion which, with the N-glycosylation capture-technique 
we use, would result in a lower yield of peptides. In the 
comparison of the two mouse models we found that 
most protein abundances were unchanged or similarly 
regulated. However, the regulation of some proteins was 
inverted in the db/db vehicle and STZ mice compared to 
the healthy control mice in the respective mouse model, 
with increased protein abundance in the diabetic mice in 
one model while decreased abundance was observed in 
the other. Some of the proteins with differentiated pro-
tein abundances are summarized with their possible rela-
tion to kidney damage or diabetes in Additional file 1e.
Most extracellular, secreted and cell surface proteins 
are N-glycosylated [30] and the majority of the proteins 
Table 3 Proteins in the top rated networks in IPA in both mouse models conform
The top rated IPA networks are shown with the included proteins together with the IPA score, the number of molecules included from the dataset and the major 
diseases and functions of the networks. Several of the same proteins were included in network 1 from both mouse models and although all networks are slightly 
overlapping, there is major overlap between networks 2–4 in both mouse models. Although the same proteins were included in the networks in both mouse models, 
they were not always regulated similarly




1 AQP2, ATP1B1, CTSV, DPEP1, EMILIN1, FAM151A, HSPA8,  
ILK, ITGA3, KLK3, MEP1A, MEP1B, PITX2, PKD1, SLC5A10, 
STUB1, SYNE1, TREH
11 13 Cell-to-cell signaling and interaction, renal and urological 
system development and function, organ morphology
2 AQP11, BICC1, CA3, CLCN5, CLU, CUBN, EGF, EGFR, ITGA1, 
ITGB1, LGMN, LRP2, SLC34A2, SOD1
6 8 Organ morphology, organismal development, renal and 
urological system development and function
3 ACE2, COL4A3, CTGF, FN1, LAMA1, LAMA5, LAMB1, LAMB2, 
LAMC1
5 6 Tissue development, decreased levels of albumin, tissue 
morphology
4 ADIPOQ, ATP2B1, BGN, CALB1, COL18A1, COL1A1,  
COL1A2, COL4A1, COL4A3, CTGF, CYP27B1, DCN, FAS, 
FBN1, FCGR2B, ICAM1, IFNG, ITGAV, KL, LEP, LUM, PARP1, 
SLC34A1, SLC9A3, SLC9A3R1, SMAD4, SMAD7, SPARC, 
TGFB1, TNF, TNFRSF1B, TRPV5, UMOD, VCAM1, VDR
5 11 Cellular movement, hematological system development 
and function, immune cell trafficking
STZ
1 AK2, ALDOB, AQP1, ATP1B1, AVPR2, DPEP1, EMILIN1, 
FAM151A, KLK3, MEP1A, MEP1B, MIOX, NAPSA, PITX2, 
PKD1, SLC5A10, TREH, TTR
10 13 Small molecule biochemistry, hematological system devel-
opment and function, tissue development
2 ACE2, ACTA2, AQP11, BICC1, CLU, COL1A1, COL1A2,  
COL4A1, COL4A3, CTGF, Ccl2, EGF, EGFR, FCGR2B, FN1, 
ICAM1, ITGA1, ITGAV, ITGB1, LAMA1, LAMA5, LAMB1, 
LAMB2, LAMC1, PARP1, PKD1, RALBP1, SMAD3, SMAD4, 
SMAD7, TGFB1, TNF, TNFRSF1B, UMOD, VEGFA
8 16 Organismal injury and abnormalities, cellular movement, 
hematological system development and function
3 BGN, COL6A3, DCN, FAS, FBN1, LUM 4 5 Hair and skin-, skeletal and muscular system-development  
and function, organ morphology
4 CA2, CALB1, CYP27B1, EZR, KL, MSN, S100G, SLC34A1, 
SLC9A3R1, TRIM24, TRPV5, VDR
3 6 Drug metabolism, lipid metabolism, molecular transport
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we identified were cell surface proteins or associated with 
the extracellular space. Interestingly, three of the four 
proteins that we identified with the inversed regulation 
in the STZ and db/db mouse models mainly reside in the 
proximal tubules in human according to The Human Pro-
tein Atlas [28]. The three mainly tubular proteins SGLT1, 
PROM1 and ALPL all had decreased protein abundances 
in the STZ and increased abundances in the db/db vehicle 
mice compared to the healthy control mice in the respec-
tive mouse model. The sodium/glucose co-transporters 
(SGLT) reabsorb glucose from the primary urine to the 
blood [31] and different expression pattern of SGLT1 in 
the two mouse models indicates that there could be DM 
type-specific differences in the protein abundance of this 
sodium glucose co-transporter. Prominin-1 is a choles-
terol binding protein in the proximal tubules. No con-
nection between DN and altered levels of PROM1 has 
previously been reported to our knowledge, but in a STZ 
mouse model of retinal vasculopathy and neuropathy, 
also secondary complications to diabetes, PROM1 in the 
photoreceptors was shown to be destroyed by metallo-
protease (MMP)-9 whereas no retinopathy or neuropathy 
was seen in MMP-9 knockout mice [32]. Those results 
indicate that the presence of PROM1 could be involved 
in reducing micro vascular damage in retinopathy since 
the lack of PROM1 is associated with retinopathy. Simi-
lar effects could take place in the proximal tubules in the 
STZ mice where PROM1 abundances were decreased 
compared to the NoSTZ healthy control mice. The tubu-
lar protein ALPL, also diametrically regulated in the STZ 
and db/db mouse models is proposed as a urinary bio-
marker for tubular damage in DN [33]. Tubular changes 
has long been known to be correlated to alterations in the 
glomerular filtration rate [34] and these changes could 
have a closer connection to the initial states of progres-
sion in DN compared to glomerular changes [35].
Several of the proteins involved in the four top-rated 


















































































































Fig. 5 The effect of insulin on the db/db mouse model. a The effect of insulin on the db/db mice away from the protein levels in the healthy db/+ 
mice. b Proteins with significant regulation in the db/db mouse model where insulin had an effect on the protein abundance towards the level in 
the healthy db/+ mice. There was no significant regulation in the STZ mouse model. Two-tailed Student’s t test was used for calculation of signifi-
cance level when 2 groups were included and one-way ANOVA with Tukey post hoc test was used for the calculations including the db/db insulin 
group in the db/db mouse model. Graphs are shown with mean and 95 % CI and P < 0.05 is considered significant
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Integrins are involved in cell adhesion, cell–matrix inter-
actions and serve as receptors for several laminin subu-
nits [9]. Here an inverse regulation of ITGB1 (β1) protein 
abundance was seen in the two mouse models (Fig.  3c) 
whilst a similar regulation of both ITGA3 (α3) and 
LAMA1 abundances were observed in the mouse models 
[36, 37]. The changes we see in the integrin and laminin 
proteins indicate that there are structural changes taking 
place in the kidney at a very early stage of DN and some 
of them could be etiology specific.
Insulin is probably the most important tool used in 
diabetes care to control hyperglycemia and thereby to 
a large degree reduce the risk of late complications like 
DN. We saw that insulin had a clear effect on several of 
the renal proteins, in general tubular [28], in the db/db 
mice, mainly in the direction of the healthy db/+ control 
mice but also in the opposite direction. The level of the 
glomerular protein SIRPA was already decreased in the 
db/db vehicle mice compared to the healthy db/+ vehi-
cle mice and insulin decreased the abundance even fur-
ther. It has been shown to interact with nephrin in the slit 
diaphragm of the podocyte [38] and could be involved in 
podocyte injury [39]. Insulin also significantly decreased 
the abundance of GPR116 similar to SIRPA in the db/db 
mice (Fig.  5a) and it has been shown in mouse adipose 
tissue that deletion of Gpr116 could cause impaired insu-
lin tolerance [40]. The unchanged protein abundance 
of GPR116 in the STZ mouse model compared to the 
decreased abundances in the db/db mice indicate mouse 
model specific differences that could be connected to an 
altered body weight in the db/db mouse.
In the majority of the proteins affected by insulin, the 
protein levels in the db/db mice were changed towards 
the levels seen in the healthy db/+ mice. The effects we 
observe of insulin on the protein abundance levels in the 
db/db mice are indicative of a protective effect. However, 
Table 4 Insulin effect on protein abundance in the db/db mouse model
In addition to the effect insulin had on some of the 27 VIP proteins, the abundances of 12 of the 153 proteins identified in both mouse models were affected by 
insulin. The protein abundance level shown as up or down and the P values are valid for the first group compared to the second group (db/db compared to the 
db/+ and db/db insulin compared to db/db respectively). Protein data is reported as in Table 2, but the STZ mouse data is not shown, as there were no significant 
differences except for in LAMA1. ALAMA1 was identified in the STZ mouse model solely with Uniprot accession P19137 and in the db/db mouse model solely 
with Uniprot accession F8VQ40 (unreviewed). The sequences share 99.7 % identity and differ in length by 1 amino acid (aa) (3084 and 3083 aa respectively). The 
abundances of P19137 and F8VQ40 were assumed comparable. BThe kidney compartment reported in the last column corresponds to the findings reported in the 
Human Protein Atlas [28]. One-way ANOVA with Tukey post hoc test for multiple comparison correction was used for P value calculations, P < 0.05 was considered 
significant. PUP putative uncharacterized protein
Uniprot ID Description Short 
name









Away from healthy control
P19137/
F8VQ40A
Laminin subunit alpha 1 LAMA1 Down <0.039 Down <0.006 G = M, T = H
G5E8Q8 Adhesion G protein-coupled recep-
tor 116
GPR116 Down <0.019 Down <0.027 ND, RNA T = H, G = L
E9Q3Q6 CD166 antigen, activated leukocyte 
cell adhesion molecule, unre-
viewed
ALCAM Up <0.018 Up <0.033 T
Insulin increases protein abundance towards healthy control
Q3TDY6 Tripeptidyl peptidase I, PUP TPP1 Down <0.005 Up <0.005 G = L, T = H
A2ARV4 Low-density lipoprotein receptor-
related protein 2
LRP2 Down <0.001 Up <0.023 T
Q8VBZ3 Cleft lip and palate associated trans-
membrane protein 1
CLPT1 Down <0.001 Up <0.01 ND, RNA T = H, G = L
Insulin reduces protein abundance towards healthy control
Q9JKR6 Hypoxia up-regulated protein 1 HYOU1 Up <0.081 Down <0.029 ND, RNA T
Q1MXF9 Sodium channel beta4 subunit, 
unreviewed
SCN4B Up <0.001 Down <0.001 G = L, T = M
Q3U4F3 Acid phosphatase 2, lysosomal, PUP ACP2 Up <0.019 Down <0.004 ND, RNA T
A2AKI5 Integrin alpha-V light chain,  
unreviewed
ITGAV Up <0.001 Down <0.016 G = H, T = M
Q3UP74 Alanyl (membrane) aminopeptidase, 
PUP
ANPEP Up <0.001 Down <0.047 T
Q9JHJ8 Inducible T-cell co-stimulator ligand ICOSL Up <0.001 Down <0.007 G = L, T = M
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in the cases where the protein levels are further away 
from the healthy db/+ mice than the levels in the db/db 
vehicle mice, the effect of insulin could either be detri-
mental or compensatory, this we do not know.
Conclusions
We focused on ECM and cell surface kidney proteom-
ics using N-linked glycosylated peptide enrichment and 
showed that there were significant protein differences 
between the STZ and db/db mouse models. Our data sug-
gests that DM type specific protein differences in the kidney 
could precede later shared morphological alterations in DN.
We also show that insulin changes the N-glycosylated 
protein abundances in the db/db mouse model both in 
the direction of the levels in the healthy control mice 
and in the opposite direction. These insulin induced 
changes in protein abundance in the db/db mouse kid-
ney could be adipose tissue related, caused by reduced 
hyperglycemia or other systemic effects of insulin in the 
mice, by insulin signaling in the kidney or could pos-
sibly compensate for the adverse effects of diabetes in 
the animals. Insulin administration, crucial for survival 
in type 1 DM but to a large extent replaceable in type 
2 DM, has a distinct effect on the N-glycosylated pro-
teome in the db/db mice that could be of high interest 




The handling and use of all animals in the present study 
was approved by The Danish Animal Experiments 
Inspectorate and was carried out according to the guide-
lines of “The Council of Europe Convention for the pro-
tection of vertebrate animals used for experimental and 
other scientific purposes”.
Male 129SV mice 6 weeks of age and male db/db and 
db/+ mice 8 weeks of age were purchased from Charles 
River, Germany and fed Altromin 1324 and tap water 
ad libitum from arrival. The animals were housed in the 
animal unit facility at Novo Nordisk, Denmark (SV129 
mice 10/cage and db/db and db/+ mice 5/cage) in con-
trolled temperature (19–21  °C for SV129 and 23–24  °C 
for db/db) and a 12 h light, 12 h dark cycle. After 2 weeks 
of acclimatization one group of randomly selected 129SV 
mice were given STZ injections intraperitoneally twice 
at a dose of 125 mg/kg with 3 days between doses. Two 
weeks post STZ intervention, BG measurements were 
conducted and mice in the STZ group (STZ) with ele-
vated BG above 16 mM were included in the experiment 
together with the group of SV129 mice that was not given 
STZ (NoSTZ). Concomitantly vehicle dosing (s.c. 4 mL/
kg QD, vehicle composition: pH 7.4; 20 mM phosphate; 
130 mM sodium chloride; 0.05 % polysorbate 80) was ini-
tiated of the STZ induced diabetic and healthy NoSTZ 
groups of mice.
After 2  weeks of acclimatization of the db/+ and db/
db mice, BG measurements were conducted and db/db 
mice with BG above 16 mM were included in the experi-
ment. The db/db mice were divided into dosing groups 
given vehicle (db/db vehicle) or insulin (db/db insulin) 
while the healthy db/+ control mice (db/+) were given 
vehicle. Vehicle composition and dosing was as with the 
STZ mice except for dosing volume (2 mL/kg) due to the 
larger size of the db/db mice. The first dose of insulin was 
2 LinBits per 20 g mouse plus 1 LinBit (LinShin Inc, Scar-
borough, ON, Canada) for each additional 5 g of mouse. 
The insulin dose was thereafter adjusted according to BG 
profiles with insulin glargine (Nomeco A/S, Copenhagen, 
Denmark) at a dose of 10 U/kg twice a day. During the 
study the animals were weighed once weekly on a digital 
scale.
In vivo measurements
Blood glucose was analyzed once weekly on a Biosen 
S-line/5040 (EKF-diagnostics, Magdeburg, Germany) 
and HbA1c% was analyzed on a Cobas 6000 autoanalyzer 
(Roche Diagnostics Ltd, Rotkreuz, Switzerland) once 
weekly for the db/db mice and at 6 and 10  weeks after 
STZ dosing for the STZ mice. Blood was taken at all time 
points from non-fasted mice before dosing.
Metabolic cages (Techniplast S.p.A., Buguggiate, Italy) 
for individual collection of urine was used at baseline, 
6 and 12 weeks (age 10, 16 and 22 weeks) for the db/db 
mice and at 2, 6 and 10 weeks (age 10, 14 and 18 weeks) 
after the STZ intervention for the STZ mice. Urine albu-
min excretion determination (AER) was determined 
using a sandwich ELISA (Bethyl Labs, Montgomery, TX, 
USA).
The animals in the db/db mouse model were sacrificed 
after 12.5 weeks of insulin dosing and the animals in the 
STZ mouse model were sacrificed 10 weeks after the STZ 
intervention by perfusion under isoflurane anesthesia 
with 20 mL 0.9 % NaCl with heparin (10 U/mL). Kidneys 
were weighed individually after having the surrounding 
fat removed and were snap frozen in liquid nitrogen. The 
left kidney from the db/db and the right kidney from the 
STZ animals were studied.
In the STZ mouse model, the total number of analyzed 
mice in the proteomics study was n = 12 with n = 6 STZ 
induced diabetic SV129 and n = 6 NoSTZ SV129 healthy 
controls, both groups dosed with vehicle. The total num-
ber of analyzed animals in the db/db mouse model part 
of the study were n = 15 with n = 5 db/db diabetic vehi-
cle dosed, n = 5 db/db diabetic insulin dosed and n = 5 
healthy db/+ control vehicle dosed mice (Fig. 1a, b).
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Protein purification
Snap frozen kidney tissue was transferred to a Dena-
tor Stabilizor T1 [41] (Denator, Gothenburg, Sweden). 
From the animals in the STZ mouse model, 50  mg of 
tissue was used resulting in one sample/animal and for 
the animals in the db/db mouse model 100  mg of tis-
sue, divided into two technical replicates, were used. 
The purification was done as described in Kurbasic et al. 
[13] based on the original paper by Zhang et al. [18]. The 
protein concentration was determined using the Micro 
Lowry assay kit Peterson’s Modification (Sigma-Aldrich, 
Stockholm, Sweden). In brief, the homogenized tissue 
was degraded with 10 μg/mL sequencing grade modi-
fied Trypsin (Promega, Madison, WI, USA) oxidized with 
sodium periodate (Serva, Heidelberg, Germany) to a final 
concentration of 8 mM and coupled to hydrazide Affi-gel 
(Bio-Rad, Hercules, CA, USA). Unbound peptides were 
washed off the hydrazide Affi-gel, where after the N-gly-
cosylated peptides were cleaved off overnight by 5 U (1 
U/μL) PNGase F (Roche Gmbh, Mannheim, Germany), 
dried on a SpeedVac (Thermo Scientific, Waltham, MA, 
USA), cleaned up by reverse-phase C18 chromatography 
(Waters, Milford, MA, USA) and dried again.
Mass spectrometry
All solvents for high performance liquid chromatogra-
phy (HPLC) were from Sigma-Aldrich and percentages 
are reported as (v/v). Samples were dissolved in 5 % ace-
tonitrile (ACN) and 0.1  % formic acid (FA) for analysis 
on an linear trap quadropole (LTQ) Orbitrap XL mass 
spectrometer (Thermo Electron, Bremen, Germany). 
Peptide separation was carried out using an Eksigent 2D 
NanoLC system (Eksigent Technologies, Dublin, CA, 
USA) where the mobile phase A was water/0.1 % FA and 
the mobile phase B was ACN/0.1 % FA. Loading, washing 
and separation was performed as in Kurbasic et al. [13]. 
Peptides were eluted from the analytical column using a 
linear gradient of mobile phase B developed from 3–35 % 
B during 60  min. The gradient was followed by 20  min 
column washing with 90 % ACN, 0.1 % FA and a 15 min 
re-equilibration with 3 % B. Peptides were analyzed using 
data-dependent acquisition, simultaneously scanning 
a mass range between 400 and 2000 Da in the Orbitrap 
and MS/MS spectra in the LTQ. Four MS/MS spectra 
were collected per second using collision-induced disso-
ciation (CID) in the LTQ ion trap. The normalized col-
lision energy was set to 35  %. Each Orbitrap MS scan 
was acquired at 60000 FWHM nominal resolution set-
tings using the lock as mass option (m/z 445.120025) for 
internal calibration. A dynamic exclusion list restricted to 
500  m/z values was used for 2  min with a repeat count 
of 2. Data was acquired using Xcalibur software, version 
2.0.7 (Thermo Fischer Scientific, Hägersten, Sweden).
Data processing
Each mouse model was examined as an individual pro-
ject and all data comparisons were made within the 
project that the samples belonged to. Raw mass spectro-
metric data were analyzed with the in-house developed 
software Proteios SE (version 2.19.0) [42] and also inde-
pendently with Progenesis QI v. 1.0.5156.29278 (Non-
linear Dynamics, Waters). In Progenesis, raw data was 
automatically aligned, manually inspected and adjusted. 
There is a built-in quality assessment in Progenesis where 
a 3-step color code for the spectrum alignment is used 
(green  =  good, beige  =  ok and red  =  needs revision). 
For both the STZ and db/db datasets, alignments were 
in good or ok agreement (green or beige). All detected 
features were exported to Mascot (MatrixScience, Lon-
don, UK) version 2.4.1 and searched against the Uni-
protKB mouse 2015.08 database with equal number of 
reversed sequences. The parent ion mass tolerance was 
set to 5 ppm and to 0.8 Da for the fragment ions and the 
MS/MS ion charge was set to 2+/3+/4+. One missed 
protease cleavage was allowed. Cys carbamidometh-
ylation was set as fixed modification and Met oxidation 
and Asn to Asp deamidation as variable modification 
(gain of 0.984 Da) as a consequence of PNGase F cleav-
age. Peptide identifications were propagated between 
runs and both peptides and proteins were filtered at 5 % 
FDR. Peptides with reverse sequences and no Asn to Asp 
modification were removed. Only proteins with a Mas-
cot score > 25 and at least one unique peptide were kept. 
Protein grouping was employed in Progenesis. No miss-
ing value imputation was done. The results from Proteios 
and Progenesis were comparable.
The mass spectrometry data have been deposited 
to the ProteomeXchange Consortium [43, 44] via the 
PRIDE partner repository with the dataset identifier 
PXD003196 and 10.6019/PXD003196 for the STZ pro-
ject and PXD003349 and 10.6019/PXD003349 for the 
db/db project. A guide to the file names is listed in an 
Additional file  1f. After peptide identification and pro-
tein assembly in Progenesis, the processed non-normal-
ized data intensities from both mouse models were run 
through the software Normalyzer 1.1.1 [45, 46]. Nor-
malyzer assesses the optimal normalization method for 
omics data sets compared to log2 transformation and 
the data sets are validated from both quantitative and 
qualitative perspectives, since the optimal normalization 
method is dependent on the intrinsic characteristics of 
the data set [45, 46]. Both the STZ and db/db data sets 
were normalized using Loess-G [47]. Mean values were 
used for the statistical analysis of technical replicates. Of 
the 153 proteins identified in both mouse models, pep-
tides with the highest scores were manually examined 
for the NXS/T motif.
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Multivariate data analysis
Unsupervised principal component analysis (PCA) and 
supervised orthogonal partial least square discriminant 
analysis (OPLS-DA) were conducted in SIMCA v. 14 
(Umetrics, Umeå, Sweden) with univariate scaling. Both 
analysis methods reduce the dimensionality in the dataset 
by introducing components that describe the joint behav-
ior of several variables. The major difference between the 
unsupervised and the supervised methods is that in the 
PCA the first component is the one describing the larg-
est co-variance within the dataset, regardless of direction 
[48] and in the OPLS-DA, the first component is class 
dependent and describes the major difference between the 
included groups, separating them on the x-axis [49]. In the 
PCA, the second component is composed of the variables 
with the largest orthogonal co-variance to the first one 
[48]. In the OPLS-DA analysis, the orthogonal difference 
takes place on the y-axis, identifying differences within 
the groups [49, 50]. The PCA and OPLS model statistics 
R2X(cum), R2Y(cum), Q2(cum) [51] and PCA compo-
nents are summarized in an Additional file 2: Panel A.
In this study, OPLS-DA was used to compare the N-gly-
cosylated proteomes of the diabetic to the healthy mice 
within the STZ and db/db mouse models and to compare 
the db/db insulin to the db/db vehicle group. The most 
important protein variables for the separation of the mouse 
groups in the OPLS-DA can be seen in the Variable Impor-
tance for the Projection (VIP)-plot. Values above 1 indicate 
importance for the OPLS model. The VIP plot of the STZ 
mouse model was compared to the VIP plot of the db/db 
mouse model not including the db/db insulin group. Pro-
teins identified both in the STZ and db/db mice with a 
VIP score above 1 were used in the comparison of the two 
mouse models. Proteins separating the db/db insulin from 
the db/db vehicle group were also examined. An overview 
of all the models is shown in Additional file 2: Panel A.
Hierarchical clustering of both the variables and mouse 
samples was done in Qlucore v. 3.2 (Qlucore AB, Lund, 
Sweden) where the cut-off level was set to P < 0.05. Pro-
teins with significant expression were evaluated using 
univariate analyses.
Statistics for univariate data
For univariate comparisons between the two groups in 
the STZ mouse model, two-tailed Student’s t test for equal 
standard deviations (SD) was performed in GraphPad Prism 
6 (La Jolla, CA, USA), which simultaneously calculates the 
F-test for equal SD. For multiple group comparisons within 
the db/db mouse model one-way ANOVA and Tukey post 
hoc test was used simultaneously with Brown-Forsythe (BF) 
test to compare intra group variance. In all tests P < 0.05 was 
considered significant. In the text, mouse parameters and 
protein data are presented as mean ± SD and in the graphs 
mouse parameters are presented with mean ± standard 
error of mean (SEM) and protein data with means and 95 % 
confidence intervals (CI). Peptide data for the 153 shared 
proteins are listed in Additional files 1a–b and protein mean 
intensities and SD for the proteins listed in Tables 2, 4 and 
Additional file 1d are reported in Additional file 1c. All cal-
culations were done in GraphPad PRISM 6, and AmberBio 
(Amber BioScience, Lund, Sweden).
Biological relationships
Protein network analysis was performed with Ingenuity 
Pathway Analysis (IPA) (Ingenuity Systems, Mountain 
View, CA, USA). In IPA, individual protein relationships 
obtained from the literature are gathered into hypotheti-
cal interaction networks [52, 53]. The MS obtained nor-
malized intensities were converted to fold change for all 
proteins comparing the diabetic to the healthy control 
mice. The two mouse models were entered separately 
into IPA and core analysis was performed for kidney tis-
sue in mice, allowing the maximum default of 35 proteins 
per network. Scores of 2 or above have 99 % confidence 
or more of not being generated by chance. The acquired 
top rated networks and canonical pathways were com-
pared between the two mouse models.
Additional files
Additional file 1. Additional file 1 includes additional excel sheets 1a-f 
where 1a shows shotgun peptide data from the STZ mouse model, formerly 
N-glycosylated peptides for the 153 common proteins, 1b shows shotgun 
peptide data from the db/db mouse model, formerly N-glycosylated pep-
tides for the common 153 proteins, 1c shows the relative mean intensities, 
SD, Mascot score, peptide count and number of unique peptides used in 
the identification of the shared proteins of importance in the multivariate 
analyses and the proteins where insulin had an effect on the abundances. 
1d shows proteins identified in both mouse models with significant protein 
abundances in the db/db mouse model but not in the STZ mouse model, 
1e show protein characteristics in relation to diabetes or kidney damage for 
a selection of the proteins with significantly changed protein abundances 
and 1f shows a conversion table of Proteome Exchange filenames and the 
corresponding kidney sample name and mouse group.
Additional file 2. Additional file 2 includes panels A-C where panel A 
shows a table of the SIMCA statistics describing the fit of the PCA and 
OPLS-DA analyses for the STZ and db/db mouse models. Values are 
between 0 and 1, where 1 is the perfect fit. R2X(cum) reflect the fraction 
of variation in X explained by the model, R2Y(cum) reflect the fraction of 
variation in Y explained by the model and Q2(cum) reflect the fraction of 
variation predicted by the model. A is the number of components in the 
model. In the PCA, the components are shown as R2X[n]. Panel B shows a 
turned 3D PCA illustration of the STZ mouse model, revealing that there is 
a degree of separation between the STZ and NoSTZ groups. The first prin-
cipal component does not separate the mouse groups. Panel C shows a 
turned 3D PCA illustration of the db/db insulin and db/db vehicle groups.
Additional file 3. Additional file 3 includes panels A and B and shows 
proteins only identified in the STZ mouse model with significant protein 
abundances. Panel A shows graphs of selected proteins significance is 
calculated with two-tailed Student’s t test for equal variance, P < 0.05 is 
considered significant. Mean and 95 % CI are shown in the graphs. Panel B 
shows a summary table for the same proteins with q-values, Mascot score, 
peptide count and number of unique peptides used in the quantification.
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Abbreviations
AER: albumin excretion rate; BG: blood glucose; BM: basement membrane; 
db/db: leptin receptor deficient; DN: diabetic nephropathy; ECM: extracel-
lular matrix; ER: endoplasmic reticulum; HbA1c%: glycated hemoglobin A1c; 
LC-MS/MS: liquid chromatography tandem mass spectrometry; OPLS-DA: 
orthogonal partial least square discriminant analysis; PCA: principle compo-
nent analysis; STZ: streptozotocin; T1DM/T2DM: type 1 or 2 diabetes mellitus.
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